Pharmacogenetics of Drugs Withdrawn from the Market

Abstract

The safety and efficacy of candidate compounds are critical factors during the development of drugs, and most drugs have been withdrawn from the market owing to severe adverse reactions. Individuals/populations with different genetic backgrounds may show significant differences in drug metabolism and efficacy, which can sometimes manifest as severe adverse drug reactions. With an emphasis on the mechanisms underlying abnormal drug effects caused by genetic mutations, pharmacogenetic studies may enhance the safety and effectiveness of drug use, provide more comprehensive delineations of the scope of usage, and change the fates of drugs withdrawn from the market.

KEYWORDS::

• adverse drug reactions
• drug withdrawn
• pharmacogenetics
• polymorphism

Financial & competing interests disclosure

This work was supported by the National Scientific Foundation of China (No. 30801421, 30901834), Huge Project to Boost Chinese Drug Development, (No.2009ZX09501–032), 863 Project (No. 2009AA022710, 2009AA022703). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This work was supported by the National Scientific Foundation of China (No. 30801421, 30901834), Huge Project to Boost Chinese Drug Development, (No.2009ZX09501–032), 863 Project (No. 2009AA022710, 2009AA022703). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.